Dunne W M, Mason E O, Kaplan S L
Department of Pathology, Baylor College of Medicine, Houston, Texas 77030-2399.
Antimicrob Agents Chemother. 1993 Dec;37(12):2522-6. doi: 10.1128/AAC.37.12.2522.
Using an equilibrium dialysis chamber, we evaluated the penetration of vancomycin, rifampin, or both through a staphylococcal biofilm to simulate treatment of an infected biomedical implant. A biofilm of ATCC 35984 (slime-positive Staphylococcus epidermidis; vancomycin MIC and MBC, 1 and 2 micrograms/ml, respectively; rifampin MIC and MBC, 0.00003 and 0.00025 micrograms/ml, respectively) was established on the inner aspect of the dialysis membrane (molecular mass exclusion, 6,000 kDa). Serum containing vancomycin (40 micrograms/ml), rifampin (20 micrograms/ml), or a combination of both was introduced into the inner chamber of the dialysis unit (in direct contact with the biofilm), and serum alone was added to the outer chamber. Rifampin and vancomycin concentrations in both chambers were determined over a 72-h period. In the absence of rifampin, the concentration of vancomycin in the outer chamber exceeded the MBC for the organism after 24 h, and the MBC increased to nearly 8.0 micrograms/ml by 72 h, demonstrating that therapeutic levels of vancomycin can penetrate a staphylococcal biofilm. However, viable bacteria were recovered from the biofilm after 72 h of treatment with no apparent increase in the MIC or MBC of vancomycin. Similarly, concentrations of rifampin exceeding the MBC were detected in the outer chamber after 24 h of treatment, but viable organisms were recovered from the biofilm after 72 h of treatment. In this case, the rifampin MBCs for surviving organisms increased from 0.00025 to > 128 micrograms/ml. The combination of agents prevented the development of resistance to rifampin, improved the perfusion of vancomycin through the biofilm, and decreased the penetration of rifampin but did not sterilize the membrane. These observations provide evidence that bactericidal levels of vancomycin, rifampin, or both can be attained at the surface of an infected implant. Despite this, sterilization of the biofilm was not accomplished after 72 h of treatment.
我们使用平衡透析室,评估万古霉素、利福平或两者通过葡萄球菌生物膜的渗透情况,以模拟感染生物医学植入物的治疗。在透析膜(分子量截留值为6000 kDa)内侧形成了ATCC 35984(产黏液表皮葡萄球菌;万古霉素的最低抑菌浓度和最低杀菌浓度分别为1和2微克/毫升;利福平的最低抑菌浓度和最低杀菌浓度分别为0.00003和0.00025微克/毫升)的生物膜。将含有万古霉素(40微克/毫升)、利福平(20微克/毫升)或两者组合的血清引入透析单元的内腔(与生物膜直接接触),并将单独的血清添加到外腔。在72小时内测定两个腔室中利福平和万古霉素的浓度。在没有利福平的情况下,24小时后外腔中万古霉素的浓度超过了该菌的最低杀菌浓度,到72小时时最低杀菌浓度增加到近8.0微克/毫升,表明治疗水平的万古霉素可以穿透葡萄球菌生物膜。然而,用万古霉素治疗72小时后,从生物膜中仍可回收存活细菌,且万古霉素的最低抑菌浓度或最低杀菌浓度没有明显增加。同样,治疗24小时后在外腔中检测到利福平的浓度超过了最低杀菌浓度,但用利福平治疗72小时后从生物膜中仍可回收存活微生物。在这种情况下,存活微生物的利福平最低杀菌浓度从0.00025增加到>128微克/毫升。联合用药可防止对利福平产生耐药性,改善万古霉素通过生物膜的灌注,并降低利福平的渗透性,但不能使透析膜无菌。这些观察结果证明,在感染植入物表面可达到杀菌水平的万古霉素、利福平或两者。尽管如此,治疗72小时后生物膜仍未被清除。